DermTech Inc (OQ:DMTK)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 12340 EL CAMINO REAL
SAN DIEGO CA 92130
Tel: N/A
Website: N/A
IR: N/A
<
Key People
Bret Christensen
President, Chief Executive Officer, Director 		Kevin M. Sun
Chief Financial Officer, Treasurer, Secretary 		Ray Akhavan
Chief Compliance Officer, General Counsel
Mark Aguillard
chief commercial officer 		   
Business Overview
DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.
Financial Overview
For the fiscal year ended 31 December 2023, DermTech Inc revenues increased 5% to $15.3M. Net loss decreased 14% to $100.9M. Revenues reflect PLA Test segment increase of 4% to $14.4M, Adhesive Patch kits segment increase from $152K to $592K. Lower net loss reflects Research and development - Balancing va decrease of 38% to $12.6M (expense), Interest income/(expense) - Balancin increase from $1.4M to $2.9M (income).
Employees: 206 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $15.30M as of Dec 31, 2023
EBITDA (TTM): -$101.93M as of Dec 31, 2023
Net annual income (TTM): -$100.89M as of Dec 31, 2023
Free cash flow (TTM): -$77.88M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 69,148,120 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More